based avid radiopharmaceuticals built pittsburgh approach developing amyvid longer lasting dye gave clinicians time scan patients early results promising eli lilly bought company 2010 $ 300 million years later fda approved amyvid test 450 imaging centers u.s. offer usually $ 3,000 fda neurological community approached amyvid mix enthusiasm trepidation officially test approved primarily exclude alzheimer diagnosis cognitive impairment particularly helpful causes unclear past january expert task force convened alzheimer association society nuclear medicine molecular imaging published guidelines advised limiting test use patients unexplained persisting mild cognitive impairment mci developed dementia unusually early dementia atypical symptoms hallucinations delirium determining alzheimer culprit